Posted by jerrympls on March 19, 2006, at 17:13:38
In reply to Re: Vicodin questions............ » BIGDaddyachmed69, posted by fairywings on March 18, 2006, at 0:51:44
>
>
> Thanks Liz and BD,
>
> Sorry about your brother Liz, I hope he's found something else to help him. I've never abused Vicodin in the sense of taking too much, but I sure don't want to start a nasty habit.
>
> fwINteresting how much abuse is brought up - I mean, it doesn't surprise me. What does surpise me is one study where Oxycontin was successfully used to help treat treatment-resistnat depression in 4 people - 3 of whom had been addicts.
Here's some more info I have gathered - just FYI:
----------------
8: Biomed Pharmacother. 1996;50(6-7):279-82.
Treatment of depressive syndromes in detoxified drug addicts: use of
methadone.Laqueille X, Bayle FJ, Spadone C, Jalfre V, Loo H.
Service Hospitalo-Universitaire de Sante Mentale et de Therapeutique,
Centre
Hospitalier Specialise Sainte-Anne, Paris, France.Depressive syndromes are very frequent in drug-addicted patients. Their
study is particularly difficult on account of the toxic intake which disturbs
the clinical analysis. Methadone has improved our understanding of these
pathologies. In fact, methadone permits treatment of some depressive
disorders typically linked to addiction, such as a motivational symptoms and
depressive mood following intoxication. It brings to the fore the other mood
disorders which are often associated with drug intake.Publication Types:
Review
Review, TutorialPMID: 8952868 [PubMed - indexed for MEDLINE]
--------------
9: J Clin Psychopharmacol. 1995 Feb;15(1):49-57.
Buprenorphine treatment of refractory depression.
Bodkin JA, Zornberg GL, Lukas SE, Cole JO.
McLean Hospital, Consolidated Department of Psychiatry, Harvard Medical
School,
Belmont, MA 02178, USA.Opiates were used to treat major depression until the mid-1950s. The
advent of opioids with mixed agonist-antagonist or partial agonist activity, with
reduced dependence and abuse liabilities, has made possible the reevaluation of
opioids for this indication. This is of potential importance for the population
of depressed patients who are unresponsive to or intolerant of
conventional antidepressant agents. Ten subjects with treatment-refractory,
unipolar, nonpsychotic, major depression were treated with the opioid partial
agonist buprenorphine in an open-label study. Three subjects were unable to
tolerate more than two doses because of side effects including malaise, nausea,
and dysphoria. The remaining seven completed 4 to 6 weeks of treatment and as
a group showed clinically striking improvement in both subjective and
objective measures of depression. Much of this improvement was observed by the end of 1 week of treatment and persisted throughout the trial. Four subjects
achieved complete remission of symptoms by the end of the trial (Hamilton Rating
Scale for Depression scores < or = 6), two were moderately improved, and
one deteriorated. These findings suggest a possible role for buprenorphine
in treating refractory depression.Publication Types:
Case Reports
Clinical TrialPMID: 7714228 [PubMed - indexed for MEDLINE]
-------------------------
10: J Subst Abuse Treat. 1990;7(1):51-4.
Depressive symptoms during buprenorphine treatment of opioid abusers.
Kosten TR, Morgan C, Kosten TA.
Department of Psychiatry, Yale University School of Medicine, New Haven,
CT.Among 40 opioid addicts treated as outpatients with sublingual
buprenorphine (2-8 mg daily) for a month, depressive symptoms significantly decreased in the 19 who were depressed at intake to treatment.PMID: 2313769 [PubMed - indexed for MEDLINE]
-----------------------
11: Int Clin Psychopharmacol. 1988 Jul;3(3):255-66.
Current and historical concepts of opiate treatment in psychiatric
disorders.Weber MM, Emrich HM.
Max-Planck-Institut fur Psychiatrie, Munchen, Federal Republic of
Germany.In recent years psychiatric research has rediscovered the theoretical
and clinical importance of opiates, especially for the understanding of
depressive disorders. However, opiate treatment is not a new therapeutic concept
in psychiatry. The use of opium for "melancholia" and "mania" may be traced to ancient classical medicine. After Paracelsus and Sydenham, the psychiatry of the German Romantic Era widely discussed therapeutic opium use with the Engelken family going on to develop a structured opium treatment of depression in the first half of the nineteenth century. Although the underlying scientific problems of psychiatric opium therapy were never solved, it gained an outstanding position as a practical treatment for over 100 years.Publication Types:
Historical ArticlePMID: 3153713 [PubMed - indexed for MEDLINE]
-----------------------1: Psychoneuroendocrinology. 1988;13(5):397-408.
Human studies on the mu opiate receptor agonist fentanyl: neuroendocrine and behavioral responses.
Hoehe M, Duka T, Doenicke A.
Psychiatric Hospital, University of Munich, F.R.G.
The neuroendocrine and behavioral responses to the potent mu opiate receptor agonist Fentanyl (FE) have been systematically investigated in healthy male volunteers. These volunteers received, according to a randomized block design, different doses of FE: 0.1 mg/70 kg (n = 11), 0.2 mg/70 kg (n = 11), 0.25 mg/70 kg (n = 8), and saline (n = 11). FE induced a pronounced dose-dependent increase of plasma prolactin concentrations, which was significant at the lowest dose. In contrast, growth hormone was significantly stimulated by the highest FE dose only. Moreover, FE induced a maximum reduction of plasma cortisol concentrations at the lowest dose (0.1 mg/70 kg). In parallel, marked euphoric responses were also observed at this lowest FE dose. These results suggest a mu specific influence on all neuroendocrine and behavioral parameters investigated. Different responses of these parameters to different doses of FE, however, suggest a differential modulation of these parameters by the mu receptor agonist FE.
Publication Types:
• Clinical Trial
• Randomized Controlled TrialPMID: 2849775 [PubMed - indexed for MEDLINE]
------------------------------------------------------------------------------
1: J Clin Psychiatry. 2001 Mar;62(3):205-6.Treatment of refractory major depression with tramadol monotherapy.
Shapira NA, Verduin ML, DeGraw JD.
Publication Types:
• Case Reports
• LetterPMID: 11305709 [PubMed - indexed for MEDLINE]
------------------------------------------------------------------------------
1: Am J Psychiatry. 1999 Dec;156(12):2017.
Treatment augmentation with opiates in severe and refractory major depression.Stoll AL, Rueter S.
Publication Types:
• Case Reports
• LetterPMID: 10588427 [PubMed - indexed for MEDLINE]
------------------------------------------------------------------------------
Prog Neuropsychopharmacol Biol Psychiatry. 2001 Feb;25(2):457-62.
Dose-dependent augmentation effect of bromocriptine in a case with refractory depression.Wada T, Kanno M, Aoshima T, Otani K.
Department of Neuropsychiatry, Yamagata University School of Medicine, Japan.
1. A 52-year-old female with refractory depression had not responded to various treatments including electroconvulsive therapy and augmentation therapy with lithium or triiodothyronine. 2. Addition of bromocriptine 2.5-5 mg/day to imipramine improved her depressive symptoms. However, when the dose was increased to 15 mg/day to treat residual depressive symptoms, her clinical status deteriorated and returned to the original level. The dose reduction to 5mg/day again improved her depressive symptoms. 3. This report confirms the augmentation effect of bromocriptine for refractory depression. It also suggests that there is dose-dependency in this effect.
Publication Types:
• Case ReportsPMID: 11294489 [PubMed - indexed for MEDLINE]
----------------------------------------------------------------------------------------------
1: Adv Biochem Psychopharmacol. 1982;32:77-84.
A possible role of opioid substances in depression.
Emrich HM.
Publication Types:
• ReviewPMID: 7046369 [PubMed - indexed for MEDLINE]
------------------------------------------------------------------------------
poster:jerrympls
thread:620477
URL: http://www.dr-bob.org/babble/20060315/msgs/622159.html